Replies to post #23802 on DNAprint Genomics (DNAG)

[mikenickels]

Brothers in arms -
Your business plan is very close to Dr. Frudakis' original plan.
The only important difference is that the development of enhanced drugs has replaced the development of drug compatibility tests. And I think that is about right. While Dr. F. has not completely dropped some of the testing products he has definitely become more interested in the production of genetically "smaty" drugs, and he has said this clearly.
As for partnering with big Pharma to market the drugs - that was always part of the plan.

regards..........

[worktoplay]

Brothers...From my admittedly limited research into EPO, there seems to be a number of serious side effects. I suspect that a "Super" EPO may be more prone to adverse events, since several of the side effects associated with commercially available EPO appear to be dose related.

In short, DNAPrint's ability to identify genetic markers predictive of response and predictive of adverse events may be the only way to get that drug to market, thus, the primary reason this drug was made available to them.

Secondarily, however, their work in this area may pay dividends even if their own EPO-EPO drug never reaches the market. Given the side effects associated with existing EPO drugs, there would seem to be a compelling need for a good classifier in the existing EPO market, which itself is $10 Billion and growing.

Of course, this is JMHO.

Later,
W2P

[bag8ger]

Brothers in Arms,

Intriguing name for a message board.!

Congratulations on your high school victory, Impressive!

I believe your understanding of DNAP's role for the future of drug development is accurate.

Robert is many of our's favorite posters.

[DorseyE]

Brothers In Arms, you said,
I would really like for you to give me your input on what I had to say, good or bad, your input counts the most.
I wish you would post more.

[Miss Scarlet]

Brothers In Arms ~

Welcome to the IHUB family - and please, don't be a stranger!

Warm Regards,

[kiyarash]

Brothers In Arms,

I like what your logic. I also think DNAP has made a progress in developing longer acting Epogen. if not why enter in such an agreeement to pay so much money? They must be at some phase of developing or near developing this long acting epogen. Currently there are two types of epogen in the market. Epogen is short acting and it is usually administered three times a week for anemia associated with cancer chemotherapy or in HIV patients or in patients who are going through kidney dialysis. As you may know the longer acting Epogen ( Aranesp ) works only two weeks. That means patient has to go to outpatient setting (hospital, doctor office, home infusion company and ....) to get the shot. Definitely there is a need to develop a tpye of epogen that can last longer than 2 weeks. There is also cost issue associated with the use of such drug. Patients, Hospitals, home infusion companies long term care facilities are saving about 40% by converting from short acting Epogen to Aranesp and that is a good reason that Aranesp is growing really fast every year and doctors are switching from Epogen or procrit to Aranesp. I also agree with you that DNAP will need a huge and successful company such as Amgen or Ortho-Mcniel to market DNAP's product if they indeed come up with such a drug.

I also believe there was a reason for DNAP not wanting to go through a joint venture with biofrontera. I think Dr. T is very smart and why share the wealth? Why focus on biofrontera when they may be near something huge? DNAP and its scientists have achieved something in the field of Epogen in the last 3 months and from the news it sounds very promising. Of course this is my opinion and all based on my understanding of the news and recent developments.

Good luck to you and by the way I am like you . I prefer to listen and read more than posting messages here.